Wikidata

(Q53183707)

English

The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)--the Israeli arm of the INNOVATE study.

scientific article published in June 2007

In more languages
default for all languages
No label defined

No description defined

Statements

title
The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)--the Israeli arm of the INNOVATE study (English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17642399
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17642399%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 January 2020

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q53183707&oldid=1193596530"